Chris Fmedsci

Chief Scientific Officer and President of Research & Development, Pfizer

Search every verified Chris Fmedsci interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a 2018 interview, Chris Boshoff, then Chief Scientific Officer and President of Research & Development at Pfizer, discussed his role as co-organizer of the upcoming Keystone Symposia meeting "Cancer Immunotherapy Combinations." He stated that the meeting would cover basic cancer research, translational immunology, and the latest insights into cancer therapy, and would be of interest to researchers and clinicians in oncology. Boshoff described checkpoint inhibitors as an established standard of care for certain cancers but noted that most patients do not respond to them or develop resistant disease. He expressed the belief that by 2025, most cancer patients would be treated with some form of immunotherapy. He highlighted the need to determine how to rationally combine immunotherapies with other treatments such as radiotherapy, chemotherapy, and targeted therapies, and emphasized the importance of preclinical data to inform correct scheduling and sequencing. He also identified molecules such as VISTA, LAG‑3, TIM‑3, ICOS, and TIGIT as potential next-generation targets for cancer immunotherapy.